Bain Capital Public Equity Management’s AstraZeneca AZN Stock Holding History

Bain Capital Public Equity Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-5,000	Closed	-$875K	–	65
2017 Q2	$875K	Buy	+5,000	New	+$327K	0.05%	54

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bain Capital Public Equity Management's AZN Position: Q2 2018 in Review

Bain Capital Public Equity Management sold out of AstraZeneca (AZN) in Q2 2018, closing a stake of 320,936 shares — an estimated $22.4M sold.

Bain Capital Public Equity Management first reported a position in AZN in Q4 2016 and held it in 4 quarters. The position peaked at $22.4M in Q1 2018. 531 funds tracked by Wall St. Rank hold AZN as of Q2 2018.

Bain Capital Public Equity Management reported no remaining AstraZeneca position as of Q2 2018 after selling out during the quarter.
Bain Capital Public Equity Management sold 320,936 AstraZeneca shares in Q2 2018, an estimated $22.4M.
Bain Capital Public Equity Management first reported a position in AstraZeneca in Q4 2016 and held it in 4 quarters.
Bain Capital Public Equity Management's AstraZeneca position peaked at $22.4M in Q1 2018.
531 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2018.

Based on Bain Capital Public Equity Management's 13F filing for Q2 2018, filed 14 Aug 2018.